Isabella Ciccone, MPH

Content Associate, @neurology_live 🧠 | @TCNJ Alum 🦁 | Former @rutgersifh Research Assistant 🔬 | 📧 [email protected] | Views are my own.

[NeurologyLive® @neurology_live]

🧠 Coming soon: Alexandra Bonner, MD, of @ClevelandClinic, on why SMA awareness matters: patients' needs evolve, requiring ongoing, multidisciplinary care.

Part of our #SMAAwarenessMonth coverage, stay tuned!

#Neurology #RareDisease

[NeurologyLive® @neurology_live]

Today’s Mind Moments episode is a special one.

We had the opportunity to sit down with @NataliaRostMD, President of the @AANmember, for a wide-ranging conversation about where the field of neurology is headed next.

From expanding brain health initiatives to tackling access to care, workforce shortages, emerging technologies, and health equity, Dr Rost shares how the AAN is thinking about the biggest priorities shaping neurologic care.

🎙 Listen in: https://t.co/bI15B9ZHHK

[NeurologyLive® @neurology_live]

🎤 🧠 We are ready to speak with experts in neuromuscular medicine at the 2026 #MDAconference!

Follow along with our coverage here: https://t.co/dfhBd0VnHa

@MDAorg @CGT_Live #MDA #MuscularDystrophy

[NeurologyLive® @neurology_live]

We’re here! In sunny San Diego ☀️🌴🌊 for the 2026 #ACTRIMSForum. What types of coverage would you like to see this week? Let us know 👇 @ACTRIMS

[NeurologyLive® @neurology_live]

🆕 Podcast: Inside MS – A Clinician’s Compass 🎙️ Ep 1: Managing MS while breastfeeding

Host Dr. Lindsay Ross & Dr. Edith Graham discuss evolving postpartum care

Listen now 👉 https://t.co/ryiHpFWj5G
#MedicalPodcast #NewPodcast #Neurology #MultipleSclerosis

[NeurologyLive® @neurology_live]

🧠💉 FDA has accepted sBLA for subcutaneous lecanemab as a weekly starting dose in early Alzheimer disease (PDUFA May 24, 2026). If approved, SC delivery could reduce infusion burden and expand access.

Our coverage: https://t.co/8gZGMcax2z

[NeurologyLive® @neurology_live]

What should neurologists actually be doing when managing functional seizures?

In this Mind Moments episode, Dr. Benjamin Tolchin, study author on the AAN guidelines, walks through the clinical reasoning behind the recommendations.

Episode highlights include:
📌 Diagnostic certainty and use of EEG and video
📌 Screening for psychiatric comorbidities
📌 Evidence supporting psychological interventions
📌 Risks of benzodiazepines and ASMs
📌 Where future research needs to go

👉 Catch the full discussion:
https://t.co/WzF6GsbzWI

[Isabella Ciccone, MPH @iciccone7]

RT @neurology_live: #BREAKING: The @US_FDA has approved inebilizumab (Uplizna; @Amgen for the treatment of generalized myasthenia gravis (g…

[NeurologyLive® @neurology_live]

#BREAKING: Full phase 3 EVOKE data for semaglutide (Ozempic; @novonordisk) have been presented. Despite consistent safety and biomarker effects, semaglutide did not outperform placebo on primary or secondary outcomes.

Our full analysis is now live:
https://t.co/wwJf9LEMN9

[NeurologyLive® @neurology_live]

Stay up to date with the latest in neurology.

From new clinical data to expert insights, here are NeurologyLive’s top stories of last week (11/23–11/29).

#Neurology #NeurologyNews #NeurologyCare

[Alzheimer's Association @alzassociation]

@iciccone7 Thank you for covering the research presented at #AAIC25 that found taking a combination of common medications for vascular disease may reduce the risk of developing dementia. https://t.co/Pucz3r0PqK

[NeurologyLive® @neurology_live]

#BREAKING: Last night, the @US_FDA approved Satsuma's dihydroergotamine nasal powder agent STS101, marketed as Atzumi, as a new treatment for patients with acute #migraine with or without aura.

https://t.co/RnMOhJsL9h

[NeurologyLive® @neurology_live]

#BREAKING: The @US_FDA has approved @JNJNews's nipocalimab, marketed as Imaavy, for the treatment of patients aged 12+ with myasthenia gravis for both anti-AChR and anti-MuSK forms🧠

More on the decision📲https://t.co/FUE47UvSVf

[NeurologyLive® @neurology_live]

🧠📘 In honor of #ParkinsonsAwareness Month, our latest Clinical Trial in Focus piece is on the phase 2 REGENERATE-PD trial of investigational gene therapy AB-1005 in patients with moderate-stage #Parkinsons disease. @ask_bio

Read Now 👇
https://t.co/HfMp94Rnp2

[NeurologyLive® @neurology_live]

Take a look at NeurologyLive's latest feature📖: a sneak peek into Cleveland Clinic's upcoming Neurological Institute, a $1.1 billion marvel set to open in early 2027. Featuring insights from Andre Machado, MD, PhD, and architect Upesh Dhaji, this piece explores the intricate details of this groundbreaking pavilion and how it aims to transform neurological care with cutting-edge, patient-centered design and innovation.

https://t.co/zM41lrblpW

[NeurologyLive® @neurology_live]

🙌🧠Thank you @AgneStraukiene for taking over the NeurologyLive X Channel during the 2025 #AANAM in San Diego, California!☀️🌴 @AANmember

In case you missed it, check out a recap of Straukiene's commentary from the meeting in the thread below 👇

[NeurologyLive® @neurology_live]

That’s wrap by Dr @AgneStraukiene from #AAN2025 in sunny San Diego! ☀️
From HSCT to Frexalimab, aging & DMTs—MS science is buzzing with hope 🐝
Thanks @NeurologyLive for letting @BeeWellWithMS take over today!
Catch more insights at 👉 https://t.co/5bNIoVd9H1
#MS #Neurology #MultipleSclerosis

[NeurologyLive® @neurology_live]

Hi, it's me again @AgneStraukiene. HSCT in aggressive #MS? Real-world data from Sheffield says: ✅
🧠 72% NEDA
📉 91.4% relapse-free
⚠️ TRM 1.1% (5/364)
Durable outcomes even in progressive MS. Risks? Real. But in expert hands—worth it.
More to come from STAR-MS!

#MultipleSclerosis #Neurology #AAN2025

[NeurologyLive® @neurology_live]

Taking over @NeurologyLive today from #AAN2025 in sunny San Diego! ☀️
I’m Dr. Agne MS Neurologist @AgneStraukiene from @BeeWellWithMS podcast 🧠
All day I’ll be serving up bold science, lived experience & MS breakthroughs—with a twist 💫
Let’s shake up neurology!
🔗 https://t.co/5bNIoVdHwz
#MS #NeuroTwitter #AAN2025 #Neurology #MultipleSclerosis

[NeurologyLive® @neurology_live]

🌴☀️Are you attending the 2025 #AANAM, held April 5-9, in San Diego, California? If so, make sure to stay up-to-date on the latest data and expert insights with our coverage! We have a great line up of interviews with experts all across different areas of #neurology, stay tuned! 🧠🎥 @AANmember

https://t.co/7pcUebJ0nj